Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 149

1.

Host-vaginal microbiota interactions in the pathogenesis of bacterial vaginosis.

Muzny CA, Łaniewski P, Schwebke JR, Herbst-Kralovetz MM.

Curr Opin Infect Dis. 2019 Nov 27. doi: 10.1097/QCO.0000000000000620. [Epub ahead of print]

PMID:
31789672
2.

Clinical validation of the Aptima Bacterial Vaginosis and Aptima Candida/Trichomonas Vaginitis Assays: results from a prospective multi-center clinical study.

Schwebke JR, Taylor SN, Ackerman R, Schlaberg R, Quigley NB, Gaydos CA, Chavoustie SE, Nyirjesy P, Remillard CV, Estes P, McKinney B, Getman DK, Clark C.

J Clin Microbiol. 2019 Nov 20. pii: JCM.01643-19. doi: 10.1128/JCM.01643-19. [Epub ahead of print]

3.

An Updated Conceptual Model on the Pathogenesis of Bacterial Vaginosis.

Muzny CA, Taylor CM, Swords WE, Tamhane A, Chattopadhyay D, Cerca N, Schwebke JR.

J Infect Dis. 2019 Sep 26;220(9):1399-1405. doi: 10.1093/infdis/jiz342.

PMID:
31369673
4.

Delay in Seeking Health Care Services After Onset of Urethritis Symptoms in Men.

Aaron KJ, Van Der Pol B, Jordan SJ, Schwebke JR, Hook EW 3rd.

Sex Transm Dis. 2019 May;46(5):317-320. doi: 10.1097/OLQ.0000000000000976.

PMID:
30985634
5.

Incubation period and risk factors support sexual transmission of bacterial vaginosis in women who have sex with women.

Muzny CA, Lensing SY, Aaron KJ, Schwebke JR.

Sex Transm Infect. 2019 Nov;95(7):511-515. doi: 10.1136/sextrans-2018-053824. Epub 2019 Mar 14.

PMID:
30872415
6.

Trichomonas vaginalis Virus Among Women With Trichomoniasis and Associations With Demographics, Clinical Outcomes, and Metronidazole Resistance.

Graves KJ, Ghosh AP, Schmidt N, Augostini P, Secor WE, Schwebke JR, Martin DH, Kissinger PJ, Muzny CA.

Clin Infect Dis. 2019 Nov 27;69(12):2170-2176. doi: 10.1093/cid/ciz146.

PMID:
30768180
7.

Incidence and predictors of reinfection with trichomoniasis based on nucleic acid amplification testing results in HIV-infected patients.

Muzny CA, Tamhane AR, Eaton EF, Hudak K, Burkholder GA, Schwebke JR.

Int J STD AIDS. 2019 Mar;30(4):344-352. doi: 10.1177/0956462418807115. Epub 2018 Nov 28.

PMID:
30486764
8.

Single-dose versus 7-day-dose metronidazole for the treatment of trichomoniasis in women: an open-label, randomised controlled trial.

Kissinger P, Muzny CA, Mena LA, Lillis RA, Schwebke JR, Beauchamps L, Taylor SN, Schmidt N, Myers L, Augostini P, Secor WE, Bradic M, Carlton JM, Martin DH.

Lancet Infect Dis. 2018 Nov;18(11):1251-1259. doi: 10.1016/S1473-3099(18)30423-7. Epub 2018 Oct 5.

9.

Identification of Key Bacteria Involved in the Induction of Incident Bacterial Vaginosis: A Prospective Study.

Muzny CA, Blanchard E, Taylor CM, Aaron KJ, Talluri R, Griswold ME, Redden DT, Luo M, Welsh DA, Van Der Pol WJ, Lefkowitz EJ, Martin DH, Schwebke JR.

J Infect Dis. 2018 Aug 14;218(6):966-978. doi: 10.1093/infdis/jiy243.

10.

Diagnostic Performance of a Molecular Test versus Clinician Assessment of Vaginitis.

Schwebke JR, Gaydos CA, Nyirjesy P, Paradis S, Kodsi S, Cooper CK.

J Clin Microbiol. 2018 May 25;56(6). pii: e00252-18. doi: 10.1128/JCM.00252-18. Print 2018 Jun.

11.

Defining the Urethritis Syndrome in Men Using Patient Reported Symptoms.

Jordan SJ, Aaron KJ, Schwebke JR, Van Der Pol BJ, Hook EW 3rd.

Sex Transm Dis. 2018 Jul;45(7):e40-e42. doi: 10.1097/OLQ.0000000000000790.

12.

In Vitro Study of the Susceptibility of Clinical Isolates of Trichomonas vaginalis to Metronidazole and Secnidazole.

Ghosh AP, Aycock C, Schwebke JR.

Antimicrob Agents Chemother. 2018 Mar 27;62(4). pii: e02329-17. doi: 10.1128/AAC.02329-17. Print 2018 Apr.

13.

Secnidazole: next-generation antimicrobial agent for bacterial vaginosis treatment.

Nyirjesy P, Schwebke JR.

Future Microbiol. 2018 Apr;13:507-524. doi: 10.2217/fmb-2017-0270. Epub 2018 Jan 12.

PMID:
29327947
14.

A Phase 3, Multicenter, Prospective, Open-Label Study to Evaluate the Safety of a Single Dose of Secnidazole 2 g for the Treatment of Women and Postmenarchal Adolescent Girls with Bacterial Vaginosis.

Chavoustie SE, Gersten JK, Samuel MJ, Schwebke JR.

J Womens Health (Larchmt). 2018 Apr;27(4):492-497. doi: 10.1089/jwh.2017.6500. Epub 2018 Jan 11.

PMID:
29323627
15.

Comparisons of vaginal flora patterns among sexual behaviour groups of women: implications for the pathogenesis of bacterial vaginosis.

Olson KM, Boohaker LJ, Schwebke JR, Aslibekyan S, Muzny CA.

Sex Health. 2018 Feb;15(1):61-67. doi: 10.1071/SH17087.

16.

Clinical Evaluation of the Cepheid Xpert TV Assay for Detection of Trichomonas vaginalis with Prospectively Collected Specimens from Men and Women.

Schwebke JR, Gaydos CA, Davis T, Marrazzo J, Furgerson D, Taylor SN, Smith B, Bachmann LH, Ackerman R, Spurrell T, Ferris D, Burnham CA, Reno H, Lebed J, Eisenberg D, Kerndt P, Philip S, Jordan J, Quigley N.

J Clin Microbiol. 2018 Jan 24;56(2). pii: e01091-17. doi: 10.1128/JCM.01091-17. Print 2018 Feb.

17.

A phase-3, double-blind, placebo-controlled study of the effectiveness and safety of single oral doses of secnidazole 2 g for the treatment of women with bacterial vaginosis.

Schwebke JR, Morgan FG Jr, Koltun W, Nyirjesy P.

Am J Obstet Gynecol. 2017 Dec;217(6):678.e1-678.e9. doi: 10.1016/j.ajog.2017.08.017. Epub 2017 Sep 1. Erratum in: Am J Obstet Gynecol. 2018 Jul;219(1):110.

PMID:
28867602
18.

Sexually transmitted infections: challenges ahead.

Unemo M, Bradshaw CS, Hocking JS, de Vries HJC, Francis SC, Mabey D, Marrazzo JM, Sonder GJB, Schwebke JR, Hoornenborg E, Peeling RW, Philip SS, Low N, Fairley CK.

Lancet Infect Dis. 2017 Aug;17(8):e235-e279. doi: 10.1016/S1473-3099(17)30310-9. Epub 2017 Jul 9. Review.

PMID:
28701272
19.

Secnidazole Treatment of Bacterial Vaginosis: A Randomized Controlled Trial.

Hillier SL, Nyirjesy P, Waldbaum AS, Schwebke JR, Morgan FG, Adetoro NA, Braun CJ.

Obstet Gynecol. 2017 Aug;130(2):379-386. doi: 10.1097/AOG.0000000000002135.

PMID:
28697102
20.

Clinical Validation of a Test for the Diagnosis of Vaginitis.

Gaydos CA, Beqaj S, Schwebke JR, Lebed J, Smith B, Davis TE, Fife KH, Nyirjesy P, Spurrell T, Furgerson D, Coleman J, Paradis S, Cooper CK.

Obstet Gynecol. 2017 Jul;130(1):181-189. doi: 10.1097/AOG.0000000000002090.

21.

Meatal Swabs Contain Less Cellular Material and Are Associated with a Decrease in Gram Stain Smear Quality Compared to Urethral Swabs in Men.

Jordan SJ, Schwebke JR, Aaron KJ, Van Der Pol B, Hook EW 3rd.

J Clin Microbiol. 2017 Jul;55(7):2249-2254. doi: 10.1128/JCM.00423-17. Epub 2017 May 10.

22.

Sexually Transmitted Infection Risk among Women Is Not Fully Explained by Partner Numbers.

Muzny CA, Harbison HS, Austin EL, Schwebke JR, Van Der Pol B, Hook EW 3rd.

South Med J. 2017 Mar;110(3):161-167. doi: 10.14423/SMJ.0000000000000621.

PMID:
28257539
23.

Pathogenesis of Bacterial Vaginosis: Discussion of Current Hypotheses.

Muzny CA, Schwebke JR.

J Infect Dis. 2016 Aug 15;214 Suppl 1:S1-5. doi: 10.1093/infdis/jiw121. Review.

24.

Trichomonas vaginalis Nucleic Acid Amplification Testing at an Urban HIV Clinic.

Muzny CA, Burkholder GA, Fry KR, Austin EL, Schwebke JR.

Sex Transm Dis. 2016 Aug;43(8):483-8. doi: 10.1097/OLQ.0000000000000479.

PMID:
27419815
25.

Home Screening for Bacterial Vaginosis to Prevent Sexually Transmitted Diseases.

Schwebke JR, Lee JY, Lensing S, Philip SS, Wiesenfeld HC, Seña AC, Trainor N, Acevado N, Saylor L, Rompalo AM, Cook RL.

Clin Infect Dis. 2016 Mar 1;62(5):531-6. doi: 10.1093/cid/civ975. Epub 2015 Nov 26.

26.

A Review of Evidence-Based Care of Symptomatic Trichomoniasis and Asymptomatic Trichomonas vaginalis Infections.

Meites E, Gaydos CA, Hobbs MM, Kissinger P, Nyirjesy P, Schwebke JR, Secor WE, Sobel JD, Workowski KA.

Clin Infect Dis. 2015 Dec 15;61 Suppl 8:S837-48. doi: 10.1093/cid/civ738. Review.

27.
28.

Management of Pelvic Inflammatory Disease in Selected U.S. Sexually Transmitted Disease Clinics: Sexually Transmitted Disease Surveillance Network, January 2010-December 2011.

Llata E, Bernstein KT, Kerani RP, Pathela P, Schwebke JR, Schumacher C, Stenger M, Weinstock HS.

Sex Transm Dis. 2015 Aug;42(8):429-33. doi: 10.1097/OLQ.0000000000000309.

29.

Accuracy of Self-Report of Sexual Activity among Adolescent Girls: Implications for Interpretation of Vaginal Flora Patterns.

Muzny CA, Schwebke JR.

MBio. 2015 Jun 23;6(3):e00819. doi: 10.1128/mBio.00819-15. No abstract available.

30.

Biofilms: An Underappreciated Mechanism of Treatment Failure and Recurrence in Vaginal Infections.

Muzny CA, Schwebke JR.

Clin Infect Dis. 2015 Aug 15;61(4):601-6. doi: 10.1093/cid/civ353. Epub 2015 May 1. Review.

31.

Editorial commentary: women who have sex with women: a unique population for studying the pathogenesis of bacterial vaginosis.

Muzny CA, Schwebke JR.

Clin Infect Dis. 2015 Apr 1;60(7):1054-6. doi: 10.1093/cid/ciu1132. Epub 2014 Dec 16. No abstract available.

PMID:
25516182
32.

Association between BVAB1 and high Nugent scores among women with bacterial vaginosis.

Muzny CA, Sunesara IR, Griswold ME, Kumar R, Lefkowitz EJ, Mena LA, Schwebke JR, Martin DH, Swiatlo E.

Diagn Microbiol Infect Dis. 2014 Dec;80(4):321-3. doi: 10.1016/j.diagmicrobio.2014.09.008. Epub 2014 Sep 16.

33.

Added benefit of nucleic acid amplification testing for the diagnosis of Trichomonas vaginalis among men and women attending a sexually transmitted diseases clinic.

Muzny CA, Blackburn RJ, Sinsky RJ, Austin EL, Schwebke JR.

Clin Infect Dis. 2014 Sep 15;59(6):834-41. doi: 10.1093/cid/ciu446. Epub 2014 Jun 13.

PMID:
24928292
34.

Reply to Hickey and Forney.

Schwebke JR, Muzny CA, Josey WE.

J Infect Dis. 2014 Nov 15;210(10):1683-4. doi: 10.1093/infdis/jiu304. Epub 2014 May 22. No abstract available.

PMID:
24855685
35.

ESwab as an optional collection device for use with the Affirm VPIII microbial test system.

Rivers CA, Lee JY, Sharples N, Ledeboer NA, Schwebke JR.

J Clin Microbiol. 2014 May;52(5):1698-700. doi: 10.1128/JCM.00048-14. Epub 2014 Feb 12.

36.

Role of Gardnerella vaginalis in the pathogenesis of bacterial vaginosis: a conceptual model.

Schwebke JR, Muzny CA, Josey WE.

J Infect Dis. 2014 Aug 1;210(3):338-43. doi: 10.1093/infdis/jiu089. Epub 2014 Feb 7. Review.

PMID:
24511102
37.

Daily temporal dynamics of vaginal microbiota before, during and after episodes of bacterial vaginosis.

Ravel J, Brotman RM, Gajer P, Ma B, Nandy M, Fadrosh DW, Sakamoto J, Koenig SS, Fu L, Zhou X, Hickey RJ, Schwebke JR, Forney LJ.

Microbiome. 2013 Dec 2;1(1):29. doi: 10.1186/2049-2618-1-29.

38.

Lack of evidence for sexual transmission of genital Candida species among women who have sex with women: a mixed methods study.

Muzny CA, Rivers CA, Parker CJ, Mena LA, Austin EL, Schwebke JR.

Sex Transm Infect. 2014 Mar;90(2):165-70. doi: 10.1136/sextrans-2013-051361. Epub 2014 Jan 15.

PMID:
24431188
39.

Detection of Trichomonas vaginalis DNA by use of self-obtained vaginal swabs with the BD ProbeTec Qx assay on the BD Viper system.

Van Der Pol B, Williams JA, Taylor SN, Cammarata CL, Rivers CA, Body BA, Nye M, Fuller D, Schwebke JR, Barnes M, Gaydos CA.

J Clin Microbiol. 2014 Mar;52(3):885-9. doi: 10.1128/JCM.02966-13. Epub 2014 Jan 3.

40.

Suspected heterosexual transmission of bacterial vaginosis without seminal fluid exposure.

Muzny CA, Schwebke JR.

Sex Transm Dis. 2014 Jan;41(1):58-60. doi: 10.1097/OLQ.0000000000000057.

PMID:
24335744
41.

Prevalence of Gardnerella vaginalis among women with lactobacillus-predominant vaginal flora.

Schwebke JR, Flynn MS, Rivers CA.

Sex Transm Infect. 2014 Feb;90(1):61-3. doi: 10.1136/sextrans-2013-051232. Epub 2013 Nov 20.

PMID:
24259188
42.

Characterization of the vaginal microbiota among sexual risk behavior groups of women with bacterial vaginosis.

Muzny CA, Sunesara IR, Kumar R, Mena LA, Griswold ME, Martin DH, Lefkowitz EJ, Schwebke JR, Swiatlo E.

PLoS One. 2013 Nov 13;8(11):e80254. doi: 10.1371/journal.pone.0080254. eCollection 2013. Erratum in: PLoS One. 2013;8(12). doi:10.1371/annotation/f7674ab1-fbd5-4293-ad2c-d1a795962e8b. Swiatlo, Edwin [added].

43.

Trichomonas vaginalis in selected U.S. sexually transmitted disease clinics: testing, screening, and prevalence.

Meites E, Llata E, Braxton J, Schwebke JR, Bernstein KT, Pathela P, Asbel LE, Kerani RP, Mettenbrink CJ, Weinstock HS.

Sex Transm Dis. 2013 Nov;40(11):865-9. doi: 10.1097/OLQ.0000000000000038.

44.

Diagnostic rates differ on the basis of the number of read days with the use of the InPouch culture system for Trichomonas vaginalis screening.

Rivers CA, Muzny CA, Schwebke JR.

J Clin Microbiol. 2013 Nov;51(11):3875-6. doi: 10.1128/JCM.02006-13. Epub 2013 Sep 4.

45.

Comparison of nucleic acid amplification assays with BD affirm VPIII for diagnosis of vaginitis in symptomatic women.

Cartwright CP, Lembke BD, Ramachandran K, Body BA, Nye MB, Rivers CA, Schwebke JR.

J Clin Microbiol. 2013 Nov;51(11):3694-9. doi: 10.1128/JCM.01537-13. Epub 2013 Aug 28.

46.

Bacterial vaginosis among African American women who have sex with women.

Muzny CA, Sunesara IR, Austin EL, Mena LA, Schwebke JR.

Sex Transm Dis. 2013 Sep;40(9):751-5. doi: 10.1097/OLQ.0000000000000004.

PMID:
23949590
47.

Intravaginal metronidazole/miconazole for the treatment of vaginal trichomoniasis.

Schwebke JR, Lensing SY, Sobel J.

Sex Transm Dis. 2013 Sep;40(9):710-4. doi: 10.1097/01.olq.0000431069.38601.d5.

PMID:
23949586
48.

The clinical spectrum of Trichomonas vaginalis infection and challenges to management.

Muzny CA, Schwebke JR.

Sex Transm Infect. 2013 Sep;89(6):423-5. doi: 10.1136/sextrans-2012-050893. Epub 2013 Mar 30. Review.

PMID:
23543252
49.

Trichomonas vaginalis infection among women receiving gynaecological care at an Alabama HIV Clinic.

Muzny CA, Rivers CA, Austin EL, Schwebke JR.

Sex Transm Infect. 2013 Sep;89(6):514-8. doi: 10.1136/sextrans-2012-050889. Epub 2013 Feb 28.

PMID:
23449600
50.

Gardnerella vaginalis: Still a Prime Suspect in the Pathogenesis of Bacterial Vaginosis.

Muzny CA, Schwebke JR.

Curr Infect Dis Rep. 2013 Apr;15(2):130-5. doi: 10.1007/s11908-013-0318-4.

PMID:
23371405

Supplemental Content

Loading ...
Support Center